Intra-articular sustained-release colchicine is efficacious in an inflammatory arthritis rat model

Area of Science:

• Rheumatology and Pharmacology
• Drug Delivery Systems

Background:

• Gout flares cause severe pain and disability, with limited treatment options for patients with contraindications.
• Existing gout flare treatments may have restricted use due to safety concerns or slow onset.
• There is a significant need for novel therapies with rapid action and favorable safety profiles.

Purpose of the Study:

• To evaluate the efficacy of intra-articular (IA) sustained-release colchicine (SR-COL) and a combination of SR-COL with ropivacaine (PKM-01) in a rat model of acute inflammatory arthritis.
• To assess the pain relief, anti-inflammatory, and joint protective effects of these novel IA treatments.

Main Methods:

• An acute inflammatory arthritis model was induced in rats using intra-articular carrageenan injection.
• Animals received intra-articular treatments including phosphate buffer saline, dexamethasone, SR-COL, ropivacaine (ROPI), or PKM-01.
• Pain was measured using Von Frey filaments and weight-bearing tests, while joint inflammation and destruction were assessed via histological scores.

Main Results:

• PKM-01 demonstrated rapid and potent analgesic effects, alongside significant anti-inflammatory properties.
• SR-COL alone also showed efficacy in reducing pain, inflammation, and joint destruction.
• Ropivacaine provided pain relief but did not significantly impact inflammation or joint destruction; blood colchicine levels remained below toxicity thresholds.

Conclusions:

• PKM-01 shows potential as an effective and safe treatment for acute inflammatory arthritis.
• The combination therapy warrants further investigation for managing conditions like gout flares.
• A clinical trial in gout flare patients is planned to validate these findings.